Pilot Simplification Study to Lopinavir/Ritonavir 800/200 mg Monotherapy Regimen Once Daily
This study has been completed.
Sponsor:
Daniel Podzamczer
ClinicalTrials.gov Identifier:
NCT01581853
First Posted: April 20, 2012
Last Update Posted: October 6, 2016
Information provided by (Responsible Party):
Daniel Podzamczer, Hospital Universitari de Bellvitge
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Lopinavir/ritonavir monotherapy is currently a well known and widely used strategy, while Lopinavir/ritonavir 800/200 mg once a day in a triple-therapy was approved a few years ago. The purpose of this study is to evaluate efficacy and safety of Lopinavir/ritonavir 800/200 mg monotherapy once a day.
| Condition | Intervention | Phase |
|---|---|---|
| HIV | Drug: Lopinavir/ritonavir 800 mg / 200mg | Phase 4 |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment |
| Official Title: | Pilot Simplification Study to Lopinavir/Ritonavir 800/200 mg Monotherapy Regimen Once Daily |
Resource links provided by NLM:
Further study details as provided by Daniel Podzamczer, Hospital Universitari de Bellvitge:
Primary Outcome Measures:
- plasma viral load <40 copies/mL [ Time Frame: Week 48 ]HIV Plasma Viral Load <40 copies/ml at week 48.
Secondary Outcome Measures:
- Stability in the plasma levels of Lopinavir/ritonavir during all study visits [ Time Frame: Weeks 4, 8, 12, 16, 24, 36 and 48 ]Determination of plasma concentrations of the study drug at weeks 4, 8, 12, 16, 24, 36 and 48
- Tolerability [ Time Frame: Weeks 4, 8, 12, 16, 24, 36 and 48 ]Possible Adverse Events will be collected in all study visits and laboratory tests will also be performed in all study visits (weeks 4, 8, 12, 16, 24, 36 and 48)
- Adherence [ Time Frame: Weeks 4, 8, 12, 16, 24, 36 and 48 ]Medication adherence will be evaluated in all the study visits after making a reconciliation of the medication dispensed and returned by the patients
- Satisfaction [ Time Frame: Weeks 4, 8, 12, 16, 24, 36 and 48 ]Patients' satisfaction with the new regimen will be evaluated using a questionnaire (SMAQ)
- - Efficacy in CSF [ Time Frame: At least 4 weeks on study treatment ]- In a subsample of patients (10) HIV-1 RNA in CSF will be assessed (added as per amendment)
| Enrollment: | 21 |
| Study Start Date: | May 2012 |
| Study Completion Date: | July 2014 |
| Primary Completion Date: | July 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Lopinavir/ritonavir 800 mg / 200mg
Kaletra 200/50 mg comprimidos recubiertos con película Lopinavir/ritonavir 800 mg / 200mg will be changed from its approved posology (2 times daily)to once daily in patients with undetectable viral load and in stable treatment with Lopinavir/ritonavir 800 mg / 200mg in monotherapy for at least 6 months
|
Drug: Lopinavir/ritonavir 800 mg / 200mg
Lopinavir/ritonavir 800 mg / 200mg will be change from its approved posology (2 times daily)to once daily in patients with undetectable viral load and in stable treatment with Lopinavir/ritonavir 800 mg / 200mg in monotherapy for at least 6 months
Other Name: Kaletra 200/50 mg comprimidos recubiertos con película
|
Eligibility
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Patients older than 18, HIV positive
- Patients receiving a monotherapy regimen (Lopinavir/ritonavir twice daily)during the last 6 months
- Undetectable viral load (<40 copies/ml) during the last 6 months
- Patients that accept participation in the study and sign the Informed Consent Form
- Childbearing females with negative pregnancy tests and using appropriate contraceptive measures
Exclusion Criteria:
- Opportunistic disease, cancer or any other active disease with specific treatment
- Active addiction to illegal drugs or active use of psychotropic drugs
- Mental retardation diagnosis, or mental dementia or severe psychiatric disorder (excluding major depression disorder solved > 3 months)
- Females who are breastfeeding or pregnant
Contacts and Locations
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01581853
Locations
| Spain | |
| Hospital del Mar | |
| Bercelona, Barcelona, Spain, 08003 | |
| Hospital Universitary de Bellvitge | |
| Hospitalet de Llobregat, Barcelona, Spain, 08907 | |
Sponsors and Collaborators
Daniel Podzamczer
Investigators
| Principal Investigator: | Daniel Podzamczer, MD | Hospital Universitari de Bellvitge |
| Principal Investigator: | Hernando Knobel, MD | Hospital del Mar |
More Information
| Responsible Party: | Daniel Podzamczer, MD. HIV/AIDS Program Director. HIV Unit. Infectious Disease Service, Hospital Universitari de Bellvitge |
| ClinicalTrials.gov Identifier: | NCT01581853 History of Changes |
| Other Study ID Numbers: |
KMON 2011-005981-39 ( EudraCT Number ) |
| First Submitted: | April 17, 2012 |
| First Posted: | April 20, 2012 |
| Last Update Posted: | October 6, 2016 |
| Last Verified: | April 2013 |
Keywords provided by Daniel Podzamczer, Hospital Universitari de Bellvitge:
|
HIV AIDS MONOTHERAPY PILOT LOPINAVIR/RITONAVIR |
Additional relevant MeSH terms:
|
Ritonavir Lopinavir HIV Protease Inhibitors Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |
Anti-HIV Agents Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents Cytochrome P-450 CYP3A Inhibitors Cytochrome P-450 Enzyme Inhibitors |